Trial Profile
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Acute Suicidal Ideation and Behavior: The SBD-ASIB Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Cycloserine/lurasidone (Primary) ; Ketamine; Lurasidone
- Indications Bipolar depression; Suicidal ideation
- Focus Registrational; Therapeutic Use
- Acronyms SBD-ASIB
- Sponsors NeuroRX; NRx Pharmaceuticals
- 17 Jan 2024 Planned End Date changed from 30 Sep 2023 to 31 Dec 2024.
- 17 Jan 2024 Planned primary completion date changed from 30 Jun 2023 to 31 Dec 2024.
- 19 Jan 2023 According to NRx Pharmaceuticals media release, the company announced that it had a meeting and written response from the FDA regarding NRX-101.